CN111462842B - Clinical application evaluation system and method for liquid chromatography-tandem mass spectrometry platform - Google Patents
Clinical application evaluation system and method for liquid chromatography-tandem mass spectrometry platform Download PDFInfo
- Publication number
- CN111462842B CN111462842B CN202010135771.7A CN202010135771A CN111462842B CN 111462842 B CN111462842 B CN 111462842B CN 202010135771 A CN202010135771 A CN 202010135771A CN 111462842 B CN111462842 B CN 111462842B
- Authority
- CN
- China
- Prior art keywords
- tandem mass
- medical institution
- project
- data
- mass spectrometry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8895—Independent juxtaposition of embodiments; Reviews
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
The invention discloses a liquid chromatography-tandem mass spectrometry platform clinical application evaluation system and a method. The invention integrates equipment and projects in the liquid chromatogram tandem mass spectrum, aims at multiple aspects of diseases, medical institutions and the like, provides a real-time updated standardized intelligent judgment mode, can provide a feasible overall solution for developing liquid quality projects for hospital planning, improves the efficiency of clinically applying a liquid chromatogram tandem mass spectrum platform, reduces repeated investment or blind investment, and has better popularization and application values.
Description
Technical Field
The invention relates to a solution for clinical application of a liquid chromatography-tandem mass spectrometry platform, and mainly relates to the technical field of clinical application of a diagnosis platform.
Background
At present, with the continuous deep understanding of human beings on diseases, clinical medical treatment enters the individualized and accurate medical stage, and the implementation of accurate medical treatment is an important precondition and guarantee for realizing the individualized diagnosis and treatment. The essence of accurate medicine is that the purpose of individual and accurate treatment of diseases and specific patients is realized through omics and medical frontier technology, and the benefit of disease diagnosis and treatment and prevention is improved. At present, the conventional clinical detection means is limited by a methodology principle, certain defects exist in the aspects of accuracy and sensitivity, in addition, the efficiency of the conventional detection is low, only one index can be detected by one-time detection, and therefore, the new requirements of clinical accurate medical treatment on diagnosis means cannot be met, and mass spectrometry detection, particularly the clinical application of a liquid chromatogram tandem mass spectrometry platform is gradually developed, so that the accurate medical treatment becomes practical.
Mass spectrometry is an analytical method for measuring ion mass-to-charge ratio (mass-to-charge ratio) and was originally invented by the british famous physicist j.j.thompson in 1906. It can be thought of as a rod-specific balance, weighing the mass of the ions. In the development history of more than 100 years, the mass spectrometry technology is continuously developed and has the advantages of rapidness, high resolution, high sensitivity, high specificity and the like. From the 80 s onwards, mass spectrometry has evolved into an industrial product, particularly the liquid chromatography tandem mass spectrometry technology, beginning to be applied to chemical analysis, life science research and pharmaceutical industry. In recent years, the demand of mass spectrometry in clinical detection is increasing, and the liquid chromatography tandem mass spectrometry becomes a marker for improving the detection capability in clinic due to the characteristics of high sensitivity, high specificity, high technology and the like, and becomes an important detection means for detecting small molecule metabolites.
Compared with the wide application of foreign mass spectrum clinical, the development of the domestic clinical mass spectrum is generally in the initial stage at present, the development is mainly concentrated in individual large-scale independent laboratories and a few hospitals, particularly liquid chromatography tandem mass spectrum platforms, the number of domestic developed projects is small, and the coverage population is low. The main problems are that the platform technology threshold is high, the types of equipment on the market are complicated, the performance levels are different, the difference of the content of the developed project is large, the clinical application aspect of the project is not standard, the cost of liquid equipment is high, and the general medical institutions can not be developed smoothly under the condition that the project prospect is not clear.
Disclosure of Invention
In order to solve the technical problems, the invention provides a clinical application evaluation system and method of a liquid chromatography tandem mass spectrometry platform, which can dynamically match and integrate project parameters, clinical application parameters of projects in different disease fields and the like by analyzing key data of a medical institution and equipment parameters of the conventional liquid chromatography tandem mass spectrometry platform, solve the current situation that the application of the liquid chromatography tandem mass spectrometry is not standardized, and provide a quick, high-efficiency and real-time updated application of the liquid chromatography tandem mass spectrometry platform for developing clinical projects for the medical institution.
The invention specifically adopts the following technical scheme:
a liquid chromatography tandem mass spectrometry platform clinical application evaluation system is characterized by comprising:
the medical institution data module is used for collecting medical institution key data, storing the medical institution key data in a computer system in an electronic database form, carrying out first intelligent analysis according to medical institution key indexes, and outputting results which are not recommended to be developed to corresponding medical institutions if the results show that the liquid chromatography tandem mass spectrometry platform projects are not suitable to be developed; if the result shows that the project is suitable for developing the liquid chromatogram tandem mass spectrometry platform, all data of the corresponding medical institution are imported into a data module of the liquid chromatogram tandem mass spectrometry platform;
the liquid chromatogram tandem mass spectrum platform data module is used for collecting information of the liquid chromatogram tandem mass spectrum equipment and dividing different levels including an entrance level, a middle level and a high level according to performance parameters of the liquid chromatogram tandem mass spectrum; according to the imported medical institution data subjected to primary screening, adding laboratory condition parameters capable of being installed by liquid chromatography tandem mass spectrometry, and performing secondary intelligent analysis, firstly, removing infeasible equipment according to the installation condition parameters, and analyzing according to key data of the medical institution in other available equipment to obtain liquid chromatography tandem mass spectrometry platform equipment of which performance level is required and the required equipment number;
the project/kit data module is used for collecting information of the liquid chromatogram tandem mass spectrum related kit, carrying out third intelligent analysis on kit information experimental data, judging whether the kit information is matched with the liquid chromatogram tandem mass spectrum equipment matched with the second intelligent analysis of the liquid chromatogram tandem mass spectrum platform data module, and importing all matched kit information into the project related disease data module;
the project related disease data module is used for generating a project disease database aimed by the kit according to the information imported by the project/kit data module, matching the project disease database with the number of beds to which main diagnosis and treatment departments of the medical institution belong, the types of main diagnosis and treatment diseases, the average hospitalization day, the direction of scientific research subjects and scientific research expenditure information, comparing the project disease database with the local medical diagnosis and treatment service project database, performing fourth intelligent analysis and screening out the most suitable clinical projects developed by the medical institution;
and the solution presentation module imports the data of the liquid chromatogram series mass spectrum project developed by the four modules aiming at the medical institution to be evaluated through four times of intelligent analysis and automatically generates a feasibility solution.
A clinical application evaluation method of a liquid chromatography-tandem mass spectrometry platform is characterized by comprising the following steps:
collecting key data of a medical institution, storing the key data in a computer system in an electronic database form, carrying out first intelligent analysis according to key indexes of the medical institution, and outputting results which are not recommended to be developed to a corresponding medical institution if the results show that the projects are not suitable for developing a liquid chromatography tandem mass spectrometry platform project; if the result shows that the project is suitable for developing a liquid chromatography tandem mass spectrometry platform project, importing all data of the corresponding medical institution into second intelligent analysis;
collecting information of liquid chromatogram tandem mass spectrum equipment, and dividing different levels including entry level, middle level and high level according to performance parameters of the liquid chromatogram tandem mass spectrum; according to the imported medical institution data subjected to primary screening, adding laboratory condition parameters capable of being installed by liquid chromatography tandem mass spectrometry, and performing secondary intelligent analysis, firstly, removing infeasible equipment according to the installation condition parameters, and analyzing according to key data of the medical institution in other available equipment to obtain liquid chromatography tandem mass spectrometry platform equipment of which performance level is required and the required equipment number;
collecting information of the liquid chromatography tandem mass spectrometry related kit, carrying out third intelligent analysis on the kit information experimental data to see whether the kit information is matched with the liquid chromatography tandem mass spectrometry equipment matched with the second intelligent analysis, and introducing all matched kit information into fourth intelligent analysis;
according to the imported adaptive kit information, generating a project disease database aimed at by the kit, matching the project disease database with the number of beds belonging to main diagnosis and treatment departments of the medical institution, the types of main diagnosis and treatment diseases, the average hospitalization date, the direction of scientific research subjects and the scientific research expenditure information, comparing the project disease database with the local medical diagnosis and treatment service project database, performing fourth intelligent analysis, and screening out the clinical projects which are most suitable for the medical institution to develop;
and the solution presentation module imports data of a liquid chromatogram series mass spectrum project developed by a medical institution to be evaluated through four times of intelligent analysis and automatically generates a feasibility solution.
The invention has the following advantages:
the invention integrates equipment and projects in the liquid chromatogram tandem mass spectrum, aims at multiple aspects of diseases, medical institutions and the like, provides a real-time updated standardized intelligent judgment mode, can provide a feasible overall solution for developing liquid quality projects for hospital planning, improves the efficiency of clinically applying a liquid chromatogram tandem mass spectrum platform, reduces repeated investment or blind investment, and has better popularization and application values.
Drawings
Fig. 1 is a block diagram of the present invention.
Detailed Description
As shown in fig. 1, the clinical application evaluation system of the liquid chromatography tandem mass spectrometry platform of the present invention comprises five modules:
1. medical institution data module
2. Data module of liquid chromatogram tandem mass spectrum platform
3. Project/kit data module
4. Project-related disease data module
5. Solution presentation module
The medical institution data module is used for collecting key data of the medical institution, and comprises attributes of the medical institution, grades of the medical institution, total number of beds, diagnosis and treatment subjects, number of beds to which main diagnosis and treatment subjects belong, main diagnosis and treatment disease types, average hospitalization days, scientific research subject directions, scientific research expenses and the like. The data sources are national health committee national medical institution query websites, medical institution official websites, medical institution on-site surveys and the like. The collected data is stored in a computer system in an electronic database form, first intelligent judgment and screening are carried out according to the grade of the medical institution, the total bed number, the main diagnosis and treatment disease types and the average key indexes of the hospital day, and if the result shows that the liquid chromatogram tandem mass spectrum platform project is not suitable for being developed, the result which is not recommended to be developed is output to the corresponding terminal medical institution. And if the result shows that the project is suitable for developing the liquid chromatogram tandem mass spectrum platform, importing all data of the corresponding terminal medical institution into a data module of the liquid chromatogram tandem mass spectrum platform for analysis.
All information in the medical institution data module can be updated in two updating modes, one is automatic maintenance updating, information is inquired in a website regularly, and the latest information is updated into a database; one is a manual update, which periodically updates offline data to a database. The rule of first intelligent judgment and screening is used for the first time, the preset rule is used, the hospital grade is more than or equal to two, the total number of beds is more than or equal to 500, cardiovascular diseases, cerebrovascular diseases, cholestasis, osteoporosis and rickets are mainly diagnosed and treated, the average hospitalization day is less than or equal to 10 days, the above conditions need to be met at the same time, and the method belongs to a liquid chromatography tandem mass spectrometry platform project.
And the liquid chromatogram tandem mass spectrum platform data module is used for collecting all the information of the liquid chromatogram tandem mass spectrum equipment which is certified by the medical instrument of the national drug administration, wherein the information comprises the equipment name, the equipment manufacturer, the equipment performance parameters and the equipment installation conditions. The equipment name, the equipment manufacturer and the equipment performance parameter information are automatically updated according to the national medical instrument inquiry website, and the equipment installation condition data are acquired through field investigation. According to the performance parameters of the current liquid chromatography tandem mass spectrum, different levels are divided, including an entrance performance level, a middle performance level and a high performance level. Inputting medical institution data subjected to primary screening in a medical institution data module into a liquid chromatogram tandem mass spectrum platform data module, adding laboratory condition parameters capable of being installed by the liquid chromatogram tandem mass spectrum, and performing secondary intelligent judgment and matching. The specific judging and matching method comprises the following steps: mass spectrometry laboratory installation basic condition parameters: the total area is more than or equal to 15 square meters, the device is provided with a water, electricity and experiment operating platform and a full-exhaust biological safety cabinet/fume hood, and medical institutions need to meet the basic conditions; gating performance level matching conditions: the hospital grade is more than or equal to two, the total bed number is more than or equal to 500, the main diagnosis and treatment disease types comprise cardiovascular diseases, cerebrovascular diseases, cholestasis, osteoporosis and rickets, and the average hospitalization day is less than or equal to 10 days; medium-level performance level matching conditions: the laboratory area is more than or equal to 20 square meters, two independent areas are required, the hospital grade is more than or equal to three, the total bed number is more than or equal to 700, the main diagnosis and treatment disease types comprise cardiovascular diseases, cerebrovascular diseases, cholestasis, osteoporosis and rickets, and the average hospitalization day is less than or equal to 10 days; advanced performance level matching conditions: the laboratory area is more than or equal to 25 square meters, three independent areas are required, the hospital grade is more than or equal to three thirds, the total bed number is more than or equal to 1000 sheets, the main diagnosis and treatment disease types comprise cardiovascular diseases, cerebrovascular diseases, digestive tract tumors, cholestasis, osteoporosis and rickets, the scientific research expenditure level of the disease types is more than or equal to 500 thousands, and the average hospitalization day is less than or equal to 9 days.
And the item/kit data module is used for collecting all information of the liquid chromatography tandem mass spectrometry related kits for obtaining the medical instrument certification of the national drug administration, wherein the information comprises the name, the manufacturer, the development item and the grade of the medical instrument, such as the first type, the second type and the third type. At present, the liquid chromatography tandem mass spectrometry kit mainly covers the items of neonatal hereditary metabolic disease, vitamins, amino acids, bile acids, fatty acids, drug concentration and the like. The data information is automatically updated according to the national medical instrument query website. And carrying out third intelligent analysis on the information experiment data of the kits to see whether the kit is matched with the liquid chromatogram tandem mass spectrum equipment intelligently matched with the liquid chromatogram tandem mass spectrum platform data module for the second time. The adaptation criteria are, the gating level: hereditary metabolic disease of newborn, vitamin D, vitamin A, vitamin E, amino acid, and drug concentration; intermediate performance level: neonatal inherited metabolic disease, full spectrum of vitamins, amino acids, drug concentrations, bile acids, fatty acids; higher performance level: neonatal inherited metabolic disease, full spectrum of vitamins, amino acids, drug concentrations, bile acids, fatty acids, and hormones. And importing all the adapted kit information into a project-related disease data module.
And the project related disease data module is used for generating a project disease database aimed by the kit according to the information imported by the project/kit data module, matching the project disease database with the number of beds of main diagnosis and treatment departments of the medical institution, the types of main diagnosis and treatment diseases, the average hospitalization day, the direction of scientific research subjects and the scientific research expenditure information, comparing the project disease database with the local medical diagnosis and treatment service project database, performing fourth intelligent analysis, and screening out the clinical projects which are most suitable for the medical institution to develop, wherein the clinical projects comprise project types, charges and annual sample volumes and aim at the diseases. The screening method comprises the following steps: judging the types of main diagnosis and treatment diseases, if the number of beds of departments related to the diseases is more than or equal to 30, and the average hospitalization day of the diagnosis and treatment diseases is less than or equal to 9 days or 10 days (according to the performance judgment of the liquid chromatography tandem mass spectrum platform), considering that the requirements of developing projects are preliminarily met, and if the performance of the liquid chromatography tandem mass spectrum platform is an advanced performance level, increasing the scientific research judgment standard, wherein the main diagnosis and treatment diseases need to be researched and researched, and the scientific research expenditure is more than or equal to 100 ten thousand; and (3) the primarily met items enter a local medical diagnosis and treatment service item database to carry out secondary judgment, relevant charging item items and charging standards are matched, bed number and average hospitalization day data are added, annual income data of the disease item are calculated, and the screening standard is developed to enable the annual income to be more than or equal to 1/4 of the construction cost of the liquid chromatogram tandem mass spectrometry platform.
The solution presenting module imports data of liquid chromatogram tandem mass spectrum projects developed by the four modules aiming at a medical institution to be evaluated through four times of intelligent analysis, and automatically generates a feasibility solution which comprises the model and the number of liquid chromatogram tandem mass spectrum devices which can be used by the medical institution, the name of the liquid chromatogram tandem mass spectrum project developed, the clinical disease type aimed by the project, the diagnosis efficiency, the number of samples which can be reached within a certain period, and the annual economic benefit.
The present invention is further illustrated by the following specific examples.
Example one
Taking a third-class hospital and the like as an example, the system disclosed by the invention is used for evaluating the clinical application scheme of the liquid chromatography tandem mass spectrometry platform.
In the data module of the medical institution, through the official website of the hospital and the related website of the national health committee, the level of the hospital is confirmed to be the public third-level class and other hospitals, and the diagnosis and treatment subjects cover the routine departments of the internal department, the external department, the women department, the children department and the like. Through the official network of the hospital, 1100 pieces of information of the total number of beds are obtained, and the hospital has two national key clinical departments, three digestive system department and gynecology department, three provincial key clinical departments, neurosurgery department, traditional Chinese medicine department and pediatrics department. The number of beds in the key clinical department and the average day of hospitalization were 4.5 days from the on-site survey. In the aspect of scientific research, annual scientific research cost is 1000 thousands, 2.5 scientific research subjects exist in the international and provincial major clinical departments on average, and the directions are main diseases in respective fields, for example, the digestive system department is mainly the research of the mechanism of gastric cancer.
The information is digitalized and semantically processed, and then the first intelligent analysis is carried out by using an algorithm, so that the evaluation result is obtained, and the method is suitable for using a liquid chromatogram tandem mass spectrum platform.
The liquid chromatography tandem mass spectrometry platform data module automatically collects latest information of liquid chromatography tandem mass spectrometry equipment for obtaining the medical instrument certification of the national drug administration, and obtains 6 types of imported equipment which are distributed in 3 manufacturers and 2 types of domestic equipment which are distributed in 2 manufacturers. And performing offline query to obtain performance parameters of various models, classifying the performance parameters into 3 types of entrance performance levels, 2 types of middle performance levels and 3 types of high performance levels according to the sensitivity, and simultaneously obtaining the installation conditions of each device. And matching the data of the third-level class A hospital with the data of the liquid chromatography tandem mass spectrometry equipment, and performing secondary intelligent analysis to obtain a conclusion that the liquid chromatography tandem mass spectrometry equipment with the medium-level performance level and above is suitable for use, wherein the optimal number is 2. The three-level class-A hospital is further matched with the reserved laboratory conditions, the space is 25 square meters, the three-level class-A hospital can be divided into two independent rooms, and the analysis result is that the three-level class-A hospital is suitable for using the middle-level performance liquid chromatography tandem mass spectrometry equipment of an import factory.
The project/kit data module automatically collects latest information of the liquid chromatography tandem mass spectrometry kit for obtaining the medical instrument certification of the national drug administration, and obtains 2 types of imported kits which are distributed in 1 manufacturer and 35 types of domestic kits which are distributed in 10 manufacturers. And carrying out 3 rd intelligent analysis on the information of the medium-grade-energy-level liquid chromatography tandem mass spectrometry equipment of an import manufacturer obtained by the intelligent analysis of the liquid chromatography tandem mass spectrometry platform data module and the kits to determine whether the information can be matched. The result is that 15 models in the domestic kit are adaptable.
The disease type corresponding to the 15 types is input into a project related disease data module, the 27 types which are removed by the 3 rd intelligent analysis are simultaneously input into the project related disease data module, the number of beds of national key clinical departments and provincial key clinical departments of the third-class A hospital is mainly used for diagnosing and treating diseases, the average hospital stay day is 4.5 days, and the scientific research fund and the scientific research direction of 1000 ten thousand years are matched, so that the 15 types which are analyzed by the 3 rd intelligent analysis can meet the requirements of the third-class hospital. The 15-type kit is compared with the medical diagnosis and treatment service item database of the province again to obtain two clinical examination items which can be used for developing bile acid and vitamin D, have charging items for mass spectrometry detection and cover all countries and provincial major clinical departments.
And the project related disease data module is used for generating a project disease database aimed by the kit according to the information imported by the project/kit data module, matching the project disease database with the number of beds of main diagnosis and treatment departments of the medical institution, the types of main diagnosis and treatment diseases, the average hospitalization day, the direction of scientific research subjects and the scientific research expenditure information, comparing the project data with the medical diagnosis and treatment service project database of each province and city, carrying out 4 th intelligent analysis, and screening out the clinical projects which are most suitable for the medical institution to develop, wherein the clinical projects comprise project types, charges and annual sample quantities and aim at the diseases.
The solution presentation module finally collects the data of the 4 times of intelligent analysis, and provides a feasible solution of a liquid chromatography tandem mass spectrometry platform for the third-class hospitals: 2 sets of the middle-grade energy-level liquid chromatography tandem mass spectrometry equipment are used for developing two clinical examination items of bile acid and vitamin D, 5 home-made reagent manufacturers can be selected, clinical auxiliary diagnosis can be performed on main diagnosis and treatment diseases in key departments of department of gastroenterology, gynecology, pediatrics, traditional Chinese medicine department and neurosurgery of the third-grade class A hospital, the annual sample size can reach 20000 cases according to the number of relevant beds of the diseases and the average hospitalization date, and the economic benefit of the third-grade class A hospital for putting into the liquid chromatography tandem mass spectrometry equipment can be guaranteed. 2 middle-grade performance-grade liquid chromatography tandem mass spectrometry equipment can assist scientific research subject directions of key departments. Has good scientific research and economic benefits.
Example two
Taking a second-level special hospital as an example, the evaluation of the clinical application scheme of the liquid chromatography tandem mass spectrometry platform is carried out.
In the medical institution data module, the official website of the hospital and the related website of the national health and health committee confirm that the hospital grade is a public second-level special hospital, and the diagnosis and treatment subjects cover the psychiatric department. Through the hospital official network, 200 pieces of information of the total number of beds are obtained, and the hospital official network has 1 city-level key clinical department and old psychiatric department. On-site survey data were obtained for 20 bed numbers in the intensive clinical department and 30 days on average. At the research level, 80 thousands of annual scientific research expenses are spent, and psychopharmacology is oriented.
The information is digitalized and semantically processed, and then the first intelligent analysis is carried out by using an algorithm, and the evaluation result is not suitable for using a liquid chromatography tandem mass spectrometry platform.
The solution presentation module collects the data of intelligent analysis and provides a solution of a liquid chromatography tandem mass spectrometry platform for the second-level special hospital: the data of bed number, clinical application departments, diseases, scientific research expenses and the like do not support the introduction of any grade of liquid chromatography tandem mass spectrometry equipment in the secondary special hospital. Compared with other hospitals of the same type in the same region, the intelligent analysis suggests that the number of beds exceeds 400, the scientific research expenditure exceeds 200 ten thousand, and the system can be put into entry-level liquid chromatography tandem mass spectrometry equipment to perform antipsychotic drug concentration monitoring projects.
Claims (8)
1. A liquid chromatography tandem mass spectrometry platform clinical application evaluation system is characterized by comprising:
the medical institution data module is used for collecting medical institution key data, storing the medical institution key data in a computer system in an electronic database form, carrying out first intelligent analysis according to medical institution key indexes, and outputting results which are not recommended to be developed to corresponding medical institutions if the results show that the liquid chromatography tandem mass spectrometry platform projects are not suitable to be developed; if the result shows that the project is suitable for developing the liquid chromatogram tandem mass spectrometry platform, all data of the corresponding medical institution are imported into a data module of the liquid chromatogram tandem mass spectrometry platform;
the liquid chromatogram tandem mass spectrum platform data module is used for collecting information of the liquid chromatogram tandem mass spectrum equipment and dividing different levels according to the performance parameters of the liquid chromatogram tandem mass spectrum, wherein the different levels comprise an entrance level, a middle level and a high level; according to the imported medical institution data subjected to primary screening, adding laboratory condition parameters capable of being installed by liquid chromatography tandem mass spectrometry, and performing secondary intelligent analysis, firstly, removing infeasible equipment according to the installation condition parameters, and analyzing according to key data of the medical institution in other available equipment to obtain liquid chromatography tandem mass spectrometry platform equipment of which performance level is required and the required equipment number;
the project/kit data module is used for collecting information of the liquid chromatogram tandem mass spectrum related kit, carrying out third intelligent analysis on kit information experimental data, judging whether the kit information is matched with the liquid chromatogram tandem mass spectrum equipment matched with the second intelligent analysis of the liquid chromatogram tandem mass spectrum platform data module, and importing all matched kit information into the project related disease data module;
the project related disease data module is used for generating a project disease database aimed by the kit according to the information imported by the project/kit data module, matching the project disease database with the number of beds to which main diagnosis and treatment departments of the medical institution belong, the types of main diagnosis and treatment diseases, the average hospitalization day, the direction of scientific research subjects and scientific research expenditure information, comparing the project disease database with the local medical diagnosis and treatment service project database, performing fourth intelligent analysis and screening out the most suitable clinical projects developed by the medical institution;
and the solution presentation module imports the data of the liquid chromatogram series mass spectrum project developed by the four modules aiming at the medical institution to be evaluated through four times of intelligent analysis and automatically generates a feasibility solution.
2. The system of claim 1, wherein the key data of the medical institution comprises attributes of the medical institution, grades of the medical institution, total number of beds, clinical subjects, number of beds belonging to main clinical subjects, main clinical disease categories, average hospital dates, directions of scientific research projects, and scientific research expenses; the data sources comprise national health committee national medical institution query websites, medical institution official websites and medical institution site surveys.
3. The system of claim 1, wherein the key indexes of the medical institution include the grade of the medical institution, the total number of beds, the type of the main clinical illness and the average hospitalization date.
4. The system of claim 1, wherein the information update of the data module of the medical institution comprises two modes: one is automatic maintenance and update, the medical institution data module periodically inquires information in a website and updates the latest information into a database; one is a manual update, which periodically updates offline data to a database.
5. The system of claim 1, wherein the lc tandem mass spectrometry device is a device for obtaining certification of medical devices of the national drug administration, and the information of the lc tandem mass spectrometry device includes a device name, a device manufacturer, device performance parameters, and device installation conditions; the equipment name, the equipment manufacturer and the equipment performance parameters are automatically updated according to the national medical instrument query website, and the equipment installation condition data is acquired through field investigation.
6. The system of claim 1, wherein all of the LC-MS related kits are kits for obtaining certification of medical devices by the State drug administration, and the information of the LC-MS related kits includes kit name, manufacturer, development project, and medical device grade; the data information is automatically updated according to the national medical instrument query website.
7. The system of claim 1, wherein the feasibility solution comprises the following: the model and the number of the liquid chromatogram tandem mass spectrum equipment which can be used by the medical institution, the name of the developed liquid chromatogram tandem mass spectrum project, the clinical disease type aimed at by the project, the diagnosis efficiency, the number of samples which can be reached within the period, and the annual economic benefit.
8. A clinical application evaluation method of a liquid chromatography-tandem mass spectrometry platform is characterized by comprising the following steps:
collecting key data of the medical institution, storing the key data in a computer system in an electronic database form, carrying out first intelligent analysis according to key indexes of the medical institution, and outputting results which are not recommended to be developed to the corresponding medical institution if the results show that the projects are not suitable for developing a liquid chromatography tandem mass spectrometry platform project; if the result shows that the project is suitable for developing a liquid chromatography tandem mass spectrometry platform project, importing all data of the corresponding medical institution into second intelligent analysis;
collecting information of liquid chromatogram tandem mass spectrum equipment, and dividing different levels including entry level, middle level and high level according to performance parameters of the liquid chromatogram tandem mass spectrum; according to the imported medical institution data subjected to primary screening, adding laboratory condition parameters capable of being installed by liquid chromatography tandem mass spectrometry, and performing secondary intelligent analysis, firstly, removing infeasible equipment according to the installation condition parameters, and analyzing according to key data of the medical institution in other available equipment to obtain liquid chromatography tandem mass spectrometry platform equipment of which performance level is required and the required equipment number;
collecting information of the liquid chromatography tandem mass spectrometry related kit, carrying out third intelligent analysis on the kit information experimental data to see whether the kit information is matched with the liquid chromatography tandem mass spectrometry equipment matched with the second intelligent analysis, and introducing all matched kit information into fourth intelligent analysis;
according to the imported adaptive kit information, generating a project disease database aimed by the kit, matching the project disease database with the number of beds to which main diagnosis and treatment departments of the medical institution belong, the types of main diagnosis and treatment diseases, the average hospitalization date, the direction of scientific research subjects and the scientific research expenditure information, comparing the project disease database with the local medical diagnosis and treatment service project database, performing fourth intelligent analysis, and screening out the most suitable clinical projects developed by the medical institution;
and the solution presentation module imports data of a liquid chromatogram series mass spectrum project developed by a medical institution to be evaluated through four times of intelligent analysis and automatically generates a feasibility solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010135771.7A CN111462842B (en) | 2020-03-02 | 2020-03-02 | Clinical application evaluation system and method for liquid chromatography-tandem mass spectrometry platform |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010135771.7A CN111462842B (en) | 2020-03-02 | 2020-03-02 | Clinical application evaluation system and method for liquid chromatography-tandem mass spectrometry platform |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111462842A CN111462842A (en) | 2020-07-28 |
| CN111462842B true CN111462842B (en) | 2023-04-07 |
Family
ID=71679983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010135771.7A Active CN111462842B (en) | 2020-03-02 | 2020-03-02 | Clinical application evaluation system and method for liquid chromatography-tandem mass spectrometry platform |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111462842B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787761B2 (en) * | 2000-11-27 | 2004-09-07 | Surromed, Inc. | Median filter for liquid chromatography-mass spectrometry data |
| JP5811023B2 (en) * | 2012-05-07 | 2015-11-11 | 株式会社島津製作所 | Data processing equipment for chromatographic mass spectrometry |
| CN109636187A (en) * | 2018-12-13 | 2019-04-16 | 重庆大学 | A kind of system for evaluating magnetic resonance equipment information |
| CN110398554A (en) * | 2019-07-31 | 2019-11-01 | 山东省食品药品检验研究院 | A kind of method and application based on Isotopic Internal Standard evaluation endogenous compound matrix effect |
-
2020
- 2020-03-02 CN CN202010135771.7A patent/CN111462842B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111462842A (en) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohamed et al. | Lipidr: a software tool for data mining and analysis of lipidomics datasets | |
| Vineis et al. | The exposome in practice: design of the EXPOsOMICS project | |
| Kosmides et al. | Metabolomic fingerprinting: challenges and opportunities | |
| Koepke et al. | Consensus building for interlaboratory studies, key comparisons, and meta-analysis | |
| CN108363908B (en) | Intelligent spectroscopy system for detecting biomolecules | |
| US8175816B2 (en) | System and method for analyzing metabolomic data | |
| US7433787B2 (en) | System, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples | |
| CN108520778A (en) | A kind of screening lung cancer system and method based on big data | |
| CN103776891B (en) | A kind of method of detection differential expression protein | |
| CN101769910A (en) | Method for screening malignant ovarian tumor markers from blood serum metabolic profiling | |
| CN112509702A (en) | Disease prediction method and system based on medical big data | |
| JP2024054240A (en) | Multimarker risk parameters predicting conversion to diabetes mellitus. | |
| Clarke et al. | Challenges in implementing clinical liquid chromatography–tandem mass spectrometry methods–seeing the light at the end of the tunnel | |
| Matos et al. | Research techniques made simple: experimental methodology for single-cell mass cytometry | |
| CN103558354A (en) | Water toxicity analysis method based on biologic omics integrated technology | |
| Taioli et al. | Methodological issues in pooled analysis of biomarker studies | |
| JP2006302222A (en) | Cancer onset risk prediction system and method, and cancer derivative method | |
| Matus et al. | 24-hour multi-omics analysis of residential sewage reflects human activity and informs public health | |
| CN111462842B (en) | Clinical application evaluation system and method for liquid chromatography-tandem mass spectrometry platform | |
| Öngür et al. | Common data elements for National Institute of Mental Health–funded translational early psychosis research | |
| Bamforth et al. | Diagnosis of inborn errors of metabolism using 1H NMR spectroscopic analysis of urine | |
| Dumas et al. | Metabolic phenotyping and systems biology approaches to understanding neurological disorders | |
| CN110322963A (en) | A kind of newborn's Inherited Metabolic Disorders determination method, apparatus and system | |
| CN113960200B (en) | Use of metabolic markers for diagnosing ADHD combined tic disorders in children | |
| Huang et al. | Traditional Chinese medicine constitution discrimination model based on metabolomics and random forest decision tree algorithm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |